- Home
- ZVIA vs NTHI Comparison
ZVIA vs NTHI Comparison
Compare ZVIA & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZVIA | NTHI |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 106.0M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ZVIA | NTHI |
|---|---|---|
| Price | $1.25 | $2.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.96 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 261.6K | 150.1K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $161,259,000.00 | $39,990.00 |
| Revenue This Year | $8.02 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $1.11 | $2.50 |
| 52 Week High | $2.78 | $12.00 |
Technical Indicators
Market Signals| Indicator | ZVIA | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 48.55 |
| Support Level | $1.13 | $2.50 |
| Resistance Level | $1.50 | $3.70 |
| Average True Range (ATR) | 0.06 | 0.29 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 59.38 | 43.70 |
Price Performance
Historical ComparisonAbout ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.